A Multicenter Phase Ib Trial for Patients with Advanced Hematologic Malignancies undergoing Allogeneic Hematopoietic Cell Transplantation with TregGraft, a T-cell-Depleted Graft with Additional Infusion of Conventional T cells and Regulatory T cells

Principal Investigator

Arpita Gandhi

Study Purpose

The purpose of the study is to learn if TregGraft, the study product, can be safely given to patients with blood cancer and pre-cancerous conditions as a blood cell transplant, and if using the study product may reduce the incidence and/or severity of the side effects associated with the standard blood stem cell transplants.

Medical Condition(s)

- Acute myeloid, lymphoid or mixed phenotype leukemia
- High or very high risk myelodysplastic syndrome
- Allogeneic stem cell transplant

Eligibility Criteria

- 18 years or older
- Diagnosis of acute myeloid, lymphoid or mixed phenotype leukemia, or high/very high risk myelodysplasic syndrome
- Planning to undergo allogenic stem cell transplant
- Matched to a related or unrelated donor
- No prior allogeneic stem cell transplant

Age Range

18 - 120

Healthy Volunteers Needed


Duration of Participation

1 year

Minors Included



Knight Cancer Intake Center: (503) 494-7999
Clinical Trials Information Line: (503) ­494-­1080 or


Orca Biosystems, INC

Recruitment End


Compensation Provided


Go Back